

**CÔNG TY
CỔ PHẦN
DƯỢC VẬT
TƯ Y TẾ
HẢI DƯƠNG**

Digitally signed by CÔNG TY CỔ
PHẦN DƯỢC VẬT TƯ Y TẾ HẢI
DƯƠNG
DN: C=VN, S=HẢI DƯƠNG, L=
Thành phố Hải Dương, CN=
CÔNG TY CỔ PHẦN DƯỢC VẬT
TƯ Y TẾ HẢI DƯƠNG,
OID.0.9.2342.19200300.100.1.1=
MST:0800011018
Reason: I am the author of this
document
Location:
Date: 2026.10.12 18:34:50+07'00'
Foxit PDF Reader Version:
2025.2.0

**HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JSC**
No.: **56**./2026-NQ/HDQT

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hai Phong, October 12, 2026

RESOLUTION

OF THE BOARD OF DIRECTORS DATED OCTOBER 12, 2026

THE BOARD OF DIRECTORS

HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, as amended by Law No. 03/2022/QH15 dated January 11, 2022, and its implementing regulations;
- Pursuant to the Charter on Organization and Operation of Hai Duong Pharmaceutical Medical Materials JSC;
- Pursuant to the Minutes of the Meeting of the Board of Directors of the Company No. **55**./2026/BB-HĐQT dated October 12, 2026.

RESOLUTION

Article 1. Approval of the Implementation Progress of Phase 2 of the HDPHARMA EU Factory Project: “Construction of Two Pharmaceutical Production Lines for Powder for Injection and Beta-lactam Antibiotics of the Cephalosporin Group, Meeting EU-GMP Standards.”

- Construction of the project has been substantially completed, and the production machinery and equipment have been installed. The final works under the Mechanical and Electrical (M&E) package are currently being completed, with completion expected in October 2026.
- Process validation (PV) for solid dosage forms of cephalosporin antibiotics is expected to be conducted in November 2026.
- The EU-GMP inspection and the qualification and validation of the two newly installed production lines are expected to take place in March 2027.

Article 2. Approval of the Project for Three Production Lines at the WHO-GMP Plant at 102 Chi Lang Street

- The total estimated investment for the injectable drug production line and the single-use eye drop and nasal drop production line is VND 48 billion. To date, VND 23.489 billion has been disbursed, including VND 11.489 billion in medium-term loans from



Vietcombank (VCB) and VND 12 billion from the Company's own funds. The factory premises are currently undergoing upgrading and renovation.

- The installation of machinery and equipment for the injectable drug production line and the eye drop and nasal drop production line is expected to be completed in 2026.
- For the BFS production line, the selection of appropriate machinery, equipment, and production technology will continue, followed by implementation of the investment project.

Article 3. Approval of Investment Activities for the Subsequent Phases of the HDPHARMA EU Factory Project in Cam Thuong

- **Building 4D:** The concept design has been completed. Detailed design, construction permit application, and tendering are expected to be carried out in preparation for commencement of construction in February–March 2027.
- **Building 4B and Building No. 3:** The preliminary plan is to complete the structural shell construction, with an estimated total investment of approximately VND 55–60 billion.
- **Project extension:** The project is currently scheduled to expire in June 2027. Preparations are required to extend the project duration by an additional two years, until June 2029.
- **Proposed implementation plan:** Maintain the existing master plan and proceed with the remaining project components, namely Buildings 4D, 4B and Building No. 3. Construction of Building 4D is expected to commence around March 2027, followed by Buildings 4B and No. 3 in approximately May–June 2028. Depending on the Company's financial situation, the Company may either proceed with structural shell construction or consider implementing the works in accordance with the prepared designs. The objective is to complete the project and settle the related project deposits and guarantees.



Article 4. Approval of the Plan to Transfer the Hanoi Branch Office in Tay Ho

- To sell the office building in Tay Ho and subsequently acquire a smaller office that better meets the Company's current operational needs, given that most of its business operations are now based in Hai Duong.

Article 5. Approval of the Preliminary Business Performance Figures for the First Nine Months of 2026 of the Company's Head Office and Five Dependent Branches Operating under Centralized Accounting

PRELIMINARY BUSINESS PERFORMANCE REPORT FOR THE FIRST NINE MONTHS OF 2026

Item	Amount (VND)
1. Revenue from Sales of Goods and Services	552,627,764,148
2. Gross Profit	196,087,035,497
3. Financial Income	323,774,430
4. Total Expenses	126,101,357,691
5. Operating Profit	61,687,277,074
6. Other Income	1,461,923,968
7. Other Expenses	486,990,251
8. Other Profit	974,933,717
9. Total Profit Before Corporate Income Tax	62,662,210,791
10. Corporate Income Tax Expense	12,532,442,158
11. Profit After Tax	50,159,768,633

Article 6. Implementation

- The Chairman and members of the Board of Directors, the General Director, and all relevant departments, divisions, units and individuals shall be responsible for implementing this Resolution.

Recipients:

- As specified in Article 6;
- Filed at the Company.

**FOR AND ON BEHALF OF THE BOARD
OF DIRECTORS
CHAIRMAN**



**CHỦ TỊCH HĐQT
NGUYỄN TRUNG VIỆT**